Oxazepam: Nursing Drug Guide, Respiratory Depression & Hold Rules
Before every dose, treat oxazepam like a sedating controlled substance: screen for opioid and other CNS depressant overlap, watch respiratory rate and sedation level, and never restart or stop abruptly without a prescriber taper plan—combined depressants and withdrawal are the bedside harms nurses must prevent.
Concomitant use of benzodiazepines (including oxazepam) with opioids or other CNS depressants may cause profound sedation, respiratory depression, coma, and death—reserve combined prescribing only when alternatives are inadequate, use minimum doses and durations, and monitor respiration and sedation. Benzodiazepines also carry risks of abuse, misuse, addiction, and overdose, especially with alcohol or other sedatives. Continued use may cause physical dependence; abrupt discontinuation or rapid dose reduction can precipitate life-threatening withdrawal (including seizures). Nurses must verify interaction checks, hold unsafe combinations, escalate respiratory depression immediately, and ensure taper instructions are documented before discharge or dose changes.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before giving oxazepam, confirm the patient is not receiving overlapping opioids, alcohol, or other CNS depressants without a clear safety plan—and assess sedation and respiratory rate before and after each dose. If respirations are shallow, the patient is difficult to arouse, or withdrawal is suspected after a missed taper, hold the dose and escalate immediately.
Most common brand names
Oxazepam is marketed as the generic Oxazepam Capsules, USP and has been known by the brand name Serax in some regions. Capsule strengths are typically 10 mg, 15 mg, and 30 mg (Schedule IV). Color-coded capsules differ by strength—verify strength on the label and MAR to prevent tenfold dosing errors.
Do not confuse oxazepam with other benzodiazepines on the MAR (lorazepam, diazepam). Duplicate benzodiazepine therapy increases sedation, fall risk, and respiratory depression—reconcile home and inpatient benzodiazepines at every transfer of care.
Why we give it — Indications
Oxazepam is an oral benzodiazepine used for short-term management of anxiety and related tension. It is not an opioid analgesic—nurses should match monitoring to CNS depression and withdrawal risk rather than pain-score targets alone.
| Use | Detail |
|---|---|
| Anxiety disorders / short-term anxiety relief | Indicated for management of anxiety disorders or short-term relief of anxiety symptoms. Everyday stress usually does not require an anxiolytic per labeling. |
| Anxiety with depression; agitation in older adults | Responsive to oxazepam when anxiety is associated with depression; labeling notes particular usefulness for anxiety, tension, agitation, and irritability in older patients—use lower starting doses and slower titration. |
| Acute alcohol withdrawal | Indicated for alcoholics with acute tremulousness, inebriation, or anxiety associated with alcohol withdrawal. Coordinate with addiction medicine and monitor for oversedation when other sedatives are used. |
| Duration of therapy | Effectiveness beyond 4 months has not been assessed by systematic clinical studies; periodic reassessment of continued need is required per labeling. |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Oxazepam is a 3-hydroxybenzodiazepinone that enhances GABAergic activity in the CNS, producing anxiolytic and sedative effects. A major inactive metabolite (glucuronide) is excreted in urine—nurses should expect additive sedation when other drugs depress the CNS (including opioids and alcohol) and should not assume renal clearance alone removes interaction risk. Tolerance to therapeutic anxiolysis may develop; cognitive and amnestic effects may persist per labeling.
Dosing overview
Dosage should be individualized for maximum benefit per labeling. Oxazepam is a Schedule IV controlled substance—follow institutional controlled-drug policies for storage, counts, and waste. Dosing must be verified against current prescribing information, prescriber order, age, hepatic/renal status, and local policy.
Pediatrics: Not indicated in patients under 6 years of age. Absolute dosage for patients 6–12 years is not established in the reviewed prescribing information.
Renal / hepatic adjustment: Not specified in the reviewed prescribing information as numeric dose reductions; labeling advises considering hepatic or renal impairment in dose selection, especially in older adults.
Missed dose: Not specified in the reviewed prescribing information. Do not double doses. If several doses are missed after chronic use, assess for withdrawal and contact prescriber before restarting—abrupt reintroduction after gaps can be unsafe.
Discontinuation: Use a gradual taper to reduce withdrawal risk per boxed warning and dosage section. If withdrawal symptoms appear during a taper, prescriber may pause taper or return to prior dose before slowing further.
Onset, peak, duration, and half-life
| Parameter | Value | Nursing relevance |
|---|---|---|
| Onset | Not specified in the reviewed prescribing information | Reassess sedation and anxiety within one dosing interval; do not stack doses for faster effect |
| Peak | ~3 hours after oral capsule/tablet/suspension (single 30 mg dose study) | Peak sedation may lag administration—monitor respirations after peak interval, especially with opioids |
| Duration | Not specified in the reviewed prescribing information | Schedule typically 3–4 times daily; align reassessment with ordered frequency |
| Half-life | Mean ~8.2 hours (range 5.7–10.9 hours); longer in very elderly (>80 y) | Accumulation and prolonged sedation possible in older adults; avoid abrupt stops after chronic use |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Review MAR and home meds for opioids, other benzodiazepines, sedating antihistamines, alcohol, and illicit CNS depressants—boxed warning applies to opioid co-use
- Assess baseline sedation, respiratory rate, blood pressure, fall risk, and mental status; screen for history of substance misuse, alcohol use disorder, or prior benzodiazepine withdrawal
- Confirm capsule strength (10 vs 15 vs 30 mg), allergy history, pregnancy intent, and whether a taper plan exists if therapy is ending; perform medication reconciliation at admission and discharge
Contraindications
- History of hypersensitivity reaction to oxazepam
- Not indicated in psychoses (do not administer solely to treat psychotic disorder without prescriber/psychiatry plan)
Important interactions
| Drug / class | Effect | Nursing action |
|---|---|---|
| Opioid analgesics | Profound sedation, respiratory depression, coma, and death; observational data show increased drug-related mortality vs opioids alone | Hold overlapping doses until prescriber/pharmacy clarifies; monitor respirations and sedation q15–30 min after co-administration per protocol; keep naloxone availability per facility policy for opioid component |
| Alcohol / other CNS depressants | Additive sedation, psychomotor impairment, and overdose risk per warnings and Medication Guide | Screen intake; educate on avoidance; escalate slurred speech, ataxia, or altered mental status |
| Other benzodiazepines | Duplicate therapy increases dependence, sedation, and respiratory depression without added benefit | Clarify single-agent plan with pharmacy; document hold if duplicate orders persist |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral capsule only (10 mg, 15 mg, 30 mg strengths). Not specified in the reviewed prescribing information for crushing/opening capsules—verify with pharmacy before altering formulation.
- Give with water; patient should remain in a safe environment after dosing because sedation and dizziness can impair mobility
- Controlled substance: follow dual-count and secure storage policies; verify patient identity and strength before every administration
- Dispense FDA Medication Guide when required by institutional policy; document patient education on opioid interaction and withdrawal risks
Labeling cautions patients not to drive or operate dangerous machinery until they know how oxazepam affects them, and warns that alcohol or other CNS-depressant effects may be additive—possibly requiring dosage adjustment or elimination of those agents. Reinforce this before discharge, especially when opioids are also prescribed.
Expected therapeutic response
- Decreased subjective anxiety, tension, irritability, or agitation without excessive somnolence
- Improved sleep quality in patients with anxiety-related insomnia when used short term—reassess need if sedation outweighs benefit
- Stable respiratory rate, blood pressure, and safe ambulation—if anxiety improves but the patient becomes obtunded, the dose may be too high or interactions present
Red flags — Stop and act
Escalate immediately for respiratory compromise, severe sedation, paradoxical agitation, withdrawal, or suspected overdose—especially with opioid or alcohol co-ingestion.
- Respiratory rate below facility threshold, shallow breathing, snoring with desaturation, or difficult arousal after a dose—hold benzodiazepine and activate emergency pathway per protocol
- Difficulty breathing, cyanosis, or apnea when combined with opioids or alcohol
- Paradoxical excitement, severe rage, hallucinations, or worsening agitation (reported with related compounds; rare with oxazepam but requires prescriber notification)
- Syncope, severe dizziness, ataxia, or fall with injury—common in older adults on benzodiazepines
- Signs of withdrawal after abrupt stop or large dose reduction: tremor, anxiety, insomnia, seizures, hallucinations—treat as emergency per labeling
- New widespread rash, fixed drug eruption, jaundice, or suspected leukopenia—stop drug and notify prescriber; periodic CBC and LFTs are advisable per labeling
Adverse effects
| Adverse effect | Frequency / severity | Nursing response |
|---|---|---|
| Transient mild drowsiness | Commonly seen in first few days; often resolves or needs dose reduction | Reassess sedation scale; hold if patient cannot be aroused or respirations are low |
| Dizziness, vertigo, headache, syncope | Reported; may occur with drowsiness | Fall precautions; orthostatic assessment; notify prescriber if recurrent |
| Paradoxical excitement / stimulation | Reported in psychiatric patients, usually first 2 weeks | Document behavior change; notify prescriber; may need alternate therapy |
| Skin rash, urticaria, fixed drug eruption | Infrequent; rare leukopenia and hepatic dysfunction including jaundice reported | Stop drug; obtain liver function tests and CBC per labeling |
| Slurred speech, tremor, ataxia, altered libido | Infrequent per labeling | Assess for toxicity vs therapeutic sedation; review interacting sedatives |
| Transient amnesia / memory impairment | Associated with benzodiazepine class | Teach family to supervise safety; evaluate continued need for therapy |
On a small screen, swipe or scroll sideways to see the full table.
Specific adverse-effect frequencies beyond qualitative terms are not provided in the reviewed prescribing information.
Overdose, toxicity, and antidote
Benzodiazepine overdose is usually manifested by varying degrees of CNS depression from drowsiness to coma. In mild cases: drowsiness, mental confusion, lethargy. In more serious cases—especially with other drugs or alcohol: ataxia, hypotonia, hypotension, hypnotic state, stage 1–3 coma, and very rarely death per labeling.
Management
- Induced vomiting and/or gastric lavage when appropriate, then supportive care, vital sign monitoring, and close observation
- Hypotension may be controlled with norepinephrine bitartrate injection per labeling; value of dialysis not adequately determined for oxazepam
- Flumazenil may be used in hospitalized patients as an adjunct to—not a substitute for—supportive management; consult complete flumazenil labeling for contraindications and seizure risk, especially with long-term benzodiazepine use or cyclic antidepressant co-ingestion
No single antidote replaces supportive care. Nursing priority: airway, breathing, circulation, continuous sedation and respiratory monitoring, and poison control / toxicology consultation per facility protocol.
Contact poison control or medical toxicology services and emergency services per facility protocol and local emergency guidance when overdose, respiratory depression, or withdrawal seizures are suspected.
Look-alike / sound-alike and error prevention
- Oxazepam vs lorazepam vs diazepam—similar names and overlapping indications; independent double-check of generic and brand on MAR
- Strength confusion—10 mg, 15 mg, and 30 mg capsules are not interchangeable; color coding varies by manufacturer
- Duplicate benzodiazepine therapy—home alprazolam plus inpatient oxazepam is a common reconciliation miss
- Opioid + benzodiazepine orders—high-risk pairing per boxed warning; requires prescriber intent and monitoring plan, not routine co-administration without review
- No specific look-alike/sound-alike pair was identified in the reviewed prescribing information beyond general benzodiazepine name similarity—standard medication-name verification still applies
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Crush/split | Not specified in the reviewed prescribing information—consult pharmacy before crushing capsules for enteral administration. |
| Food timing | Not specified in the reviewed prescribing information. |
| Enteral tube | Not specified in the reviewed prescribing information—pharmacy should advise on liquid alternatives if available. |
| Storage | Store at 20–25°C (68–77°F); protect from moisture; dispense in tight, light-resistant container per labeling. |
| Lab timing | Periodic blood counts and liver-function tests advisable during therapy per adverse-reactions section. |
| Commonly missed | PRN benzodiazepine given while scheduled opioid PCA is running; alcohol use not documented; no taper on discharge after inpatient use. |
| Ask pharmacy when | Opioid co-therapy questions, controlled-substance discrepancies, taper orders, or enteral tube administration. |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Older adults | Greater sensitivity to sedation, hypotension, and paradoxical excitation cannot be ruled out; start at lower dosing range; very elderly (>80 y) have longer half-life per pharmacology section |
| Hepatic / renal impairment | Clinical circumstances including hepatic or renal impairment should be considered in dose selection; periodic LFTs and CBC advisable per labeling |
| Cardiovascular disease | Administer with caution if blood pressure drop could worsen cardiac status; hypotension has occurred rarely per precautions |
| History of substance misuse | Boxed warning: assess abuse, misuse, and addiction risk before and during therapy; avoid concomitant alcohol and illicit CNS depressants |
| Pregnancy | Related minor tranquilizers have been associated with increased congenital malformations in some first-trimester studies; oxazepam not studied adequately—avoid when possible; consider pregnancy before starting therapy |
| Lactation | LactMed states oxazepam is excreted into breast milk and may cause sedation in the infant; an alternate agent may be preferred, especially in newborn/preterm infants—discuss risks with prescriber |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Respiratory rate, depth, and oxygenation before and after each dose—especially with opioid co-therapy; pair pain scoring with sedation scales per protocol
- Level of consciousness, fall risk, ambulation safety, and paradoxical agitation or confusion
- Blood pressure in older adults; periodic CBC and liver function tests when prolonged therapy or hepatic symptoms per labeling
Document
- Dose (mg), capsule strength, route, time, indication, and prescriber
- Pre-dose sedation/respiratory assessment and post-dose response; any hold actions and notifications
- Medication Guide/teaching on opioid interaction, alcohol avoidance, driving restrictions, taper plan, and safe storage (Schedule IV)
Patient teaching
- Take exactly as prescribed; do not share medication; store securely—oxazepam is a controlled substance with abuse potential per Medication Guide
- Do not drink alcohol or take other sedating medicines (including opioid pain medicines) unless your prescriber approves—risk of severe drowsiness, breathing problems, coma, and death
- Do not drive or operate machinery until you know how oxazepam affects you; sedation may worsen at peak effect (~3 hours after a dose per labeling pharmacology)
- Do not stop suddenly—withdrawal can be life-threatening; contact prescriber for taper instructions if therapy ends
- Seek emergency care for trouble breathing, cannot be awakened, seizures, suicidal thoughts, or severe rash—contact poison control or toxicology services per local guidance for suspected overdose
The Hold Rule
Do not give and contact the prescriber/pharmacist when:
- Known oxazepam allergy or active hypersensitivity (rash, angioedema)
- Respiratory rate or oxygen saturation below prescriber/facility threshold, difficult arousal, or suspected overdose
- Unsafe concurrent opioid or CNS depressant without prescriber-approved plan and monitoring
- Order intended for psychosis as sole therapy (not an indicated use) or duplicate benzodiazepine on MAR
- Patient actively withdrawing from alcohol/benzodiazepines without protocol—clarify taper vs new sedating dose with prescriber
- Capsule strength or dose unclear (10 vs 15 vs 30 mg error) or controlled-substance count discrepancy
Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.
Clinical practice integration and workflow
Oxazepam is often ordered for alcohol withdrawal or geriatric agitation, but the boxed warning makes opioid overlap and respiratory monitoring non-optional. Build interaction screening and sedation scoring into every medication pass—not only at admission.
1. Check-before-you-give protocol
- Right patient, drug, dose (mg strength), route, time—and controlled-substance verification
- Screen MAR for opioids, other benzodiazepines, and PRN sedatives; review last alcohol intake when relevant
- Pre-dose respiratory rate, SpO2 if ordered, sedation level, and fall-risk status
- Confirm taper or continuation plan if therapy >4 months or discharge is planned
2. High-alert and safety badge
Schedule IV controlled substance with boxed warning—not on all institutional high-alert listsApply high-alert medication administration rigor for opioid–benzodiazepine combinations: independent double-check, enhanced respiratory monitoring, and clear escalation thresholds even when oxazepam alone is not listed as high-alert.
3. Clinical workflow: hold and question rules
- If respirations are shallow or the patient is somnolent before the dose, hold and contact prescriber/pharmacy—do not administer “because it is scheduled”
- If a new opioid PCA or oral opioid starts, reassess whether oxazepam remains necessary and at what reduced dose
- Any suspected withdrawal seizure, overdose, or inability to arouse the patient triggers emergency escalation and poison control/toxicology per protocol
4. Critical teach-back questions
- “What should you avoid while taking oxazepam?” (Patient should name alcohol, other sedating medicines including opioids unless prescriber approved, and driving until effects are known.)
- “What do you do if you miss doses or want to stop?” (Patient should state they will call the prescriber for taper instructions and not stop suddenly because withdrawal can be dangerous.)
5. Care coordination
Pharmacist: Interaction review (opioids/CNS depressants), controlled-substance reconciliation, taper design, and overdose/flumazenil guidance
Prescriber / mental health or addiction services: Notify for paradoxical reactions, dependence concerns, panic disorder management changes, or prolonged therapy reassessment
🧠 Quick mental checklist
- Is the patient also on opioids, alcohol, or another benzodiazepine right now?
- What were respirations and sedation level before this dose—and what is the plan if they drop after peak effect?
- Is this the correct capsule strength (10 vs 15 vs 30 mg) for the order?
- If therapy is ending, is there a written taper—not an abrupt stop?
- Does the patient have fall-risk precautions and safe mobility support after dosing?
Oxazepam NCLEX practice questions
Practice NCLEX-style clinical judgment practice for oxazepam using a tabbed case (MAR, labs, vitals, nursing notes), then priority action, cue recognition (SATA), respiratory trend interpretation, matrix urgency sorting, hold/monitoring judgment, and cloze withdrawal teaching—recognise cues → analyse → prioritise → act → evaluate outcomes.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- Oxazepam 15 mg PO TID — 0800 given; 1400 due now
- Morphine sulfate 2 mg IV q4h PRN severe pain — 1 mg given at 1300 (pain 7/10)
- No other scheduled benzodiazepines on MAR
- CIWA protocol not ordered; oxazepam continued for generalized anxiety
- AST 24 U/L, ALT 28 U/L, bilirubin WNL (admission)
- CBC WNL; no prior leukopenia documented
- BMP WNL this morning
- 1200: RR 14, SpO2 96% on room air, BP 118/72, HR 88, temp 36.8 °C
- 1330 (after morphine 1 mg): RR 11, SpO2 94%, BP 104/68, HR 82
- 1350: patient drowsy but arousable to voice; denies pain (score 2/10)
- 1400 (now): RR 9, SpO2 91%, BP 102/64, HR 78
- 68-year-old admitted for alcohol withdrawal monitoring day 2; reports last drink 48 h ago
- 0900: Family brought home lorazepam bottle—patient took 0.5 mg “for nerves” before arrival (not on MAR)
- 1335: Nurse held oxazepam 0800 dose in error—pharmacy clarified scheduled dose is appropriate if respirations safe
- 1400: Preparing 1500 oxazepam; concerned about overlapping sedatives after PRN morphine
Answer key & rationale
Frequently asked questions
Can oxazepam be given with opioid pain medication?
FDA labeling warns that concomitant benzodiazepines and opioids may cause profound sedation, respiratory depression, coma, and death. Reserve combined use for patients without adequate alternatives, use the lowest effective doses for the shortest duration, and monitor closely. Hold and contact the prescriber or pharmacist when unsafe overlap is present.
When should a nurse hold oxazepam?
Hold for known oxazepam allergy, psychosis as sole indication, excessive sedation or respiratory depression, suspected overdose, new serious rash or hypersensitivity, unsafe concurrent opioids or CNS depressants without prescriber clearance, or unclear capsule strength/dose.
What happens if oxazepam is stopped suddenly?
Prescribing information states abrupt discontinuation or rapid dosage reduction after continued use may precipitate acute withdrawal reactions that can be life-threatening, including seizures. Use a gradual prescriber-directed taper and teach patients not to stop suddenly.
What vitals and assessments should nurses monitor with oxazepam?
Monitor sedation level, respiratory rate and effort, blood pressure, fall risk, mental status, and paradoxical agitation. Periodic blood counts and liver-function tests are advisable per labeling during continued therapy.
Is oxazepam safe during pregnancy or breastfeeding?
Labeling advises avoiding use during pregnancy when possible because related minor tranquilizers have been associated with increased congenital malformations in some studies and oxazepam has not been studied adequately. LactMed notes oxazepam enters breast milk and may sedate the infant—an alternate drug may be preferred, especially in newborn or preterm infants.
What is used to treat benzodiazepine overdose?
Overdose management is primarily supportive with vital sign monitoring. Flumazenil may be used in hospitalized patients as an adjunct; labeling warns of seizure risk, especially with long-term benzodiazepine use. Contact poison control or medical toxicology services per facility protocol and local emergency guidance.
References
-
U.S. National Library of Medicine. Oxazepam Capsules, USP — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bda8bc70-3328-46f2-89d5-7ef7a061b418
-
U.S. National Library of Medicine. Oxazepam — Medication Guide. DailyMed.https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=bda8bc70-3328-46f2-89d5-7ef7a061b418
-
Drugs and Lactation Database (LactMed). Oxazepam. Bethesda (MD): National Institute of Child Health and Human Development.https://www.ncbi.nlm.nih.gov/books/n/lactmed/LM377/
-
U.S. Food and Drug Administration. Drug Safety and Availability.https://www.fda.gov/drugs/drug-safety-and-availability
-
U.S. Centers for Disease Control and Prevention. Overdose prevention.https://www.cdc.gov/overdose-prevention/prevention/index.html
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.